Scientific Zambon Pharma December 11, 2018 NON–CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) FDA GRANTS “FAST-TRACK” AND “QIPD” TO ZAMBON FOR COLISTIMETHATE SODIUM POWDER FOR NEBULIZER SOLUTION DELIVERED BYTHE I-NEB AAD SYSTEM.
Scientific Zambon Pharma November 30, 2018 Zambon announces approval and ARTG listing of Safinamide in Australia for treatment of patients with Parkinson’s disease
Institutional Zambon Pharma November 13, 2018 AstraZeneca and Zambon Announce a Strategic Partnership at CIIE
Scientific Zambon Pharma July 11, 2017 XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE PATIENTS
Institutional Zambon Pharma April 11, 2017 Valeo Pharma and Zambon form partnership for Parkinson’s Disease Treatment Xadago® (safinamide) in Canada
Scientific Zambon Pharma April 10, 2017 ZAMBON LAUNCHES XADAGO® (SAFINAMIDE) IN PORTUGAL FOR PATIENTS WITH MID- TO LATE-STAGE PARKINSON’S DISEASE
Scientific Zambon Pharma March 21, 2017 FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS